[Clinical evaluation of effects from neo-adjuvant chemotherapy with @entity1259 plus @entity1311 in cases of locally advanced XXXX ].

@entity1 @entity4444 @entity3933 @entity137 @entity3974 @entity0 @entity1671 @entity5 @entity1259 @entity1311 @entity619 @entity1398 @entity4841 @entity925
Neo-adjuvant chemotherapy of @entity1259 plus @entity1311 was administered to 23 @entity1 with locally advanced @entity0 (including 13 cases of stage IIb, 6 of stage IIIa, and 4 of stage IIIb). All @entity1 were female. They were treated with @entity1259 60 mg/m2, on day 1, by i.v. followed @entity1311 150 mg/m2 by 3 hours continuous infusion on day 2 and every 3 weeks repeatedly. Premedication with @entity619 , @entity3974 , @entity3933 and @entity4444 were administered to prevent gastroenteric and allergic reactions before chemotherapy. Two to 4 cycles were used. Ten out of 23 @entity1 had a complete response, 10 had partial response, and 3 had no change. The response rate was 87% (20/23). Six out of 23 @entity1 underwent breast conserving surgery as @entity5 size had become smaller and downstaging was realized after neo-adjuvant chemotherapy. The major @entity137 included @entity1398 , @entity925 , @entity4841 , nephrotoxicity, gastroenteric reactions, alopecia and @entity1671 to the face. However, these were well tolerated in these @entity1 .
